Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 22, 2025
CHANGES OF CORPORATE OFFICERS
-
December 11, 2025
Eisai Rated “A”, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
-
December 9, 2025
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
-
December 4, 2025
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from MCI to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage
New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States
-
December 3, 2025
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
-
December 2, 2025
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in phase Ib/II study
-
November 28, 2025
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease
-
November 26, 2025
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless disease
-
November 19, 2025
Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer’s Disease Conference
Latest findings from Eisai's robust Alzheimer's disease pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of subcutaneous administration of lecanemab for initiation dosing
Oral and poster presentations also include data on the effects of lecanemab on soluble amyloid-β protofibrils and insights from real-world clinical practice studies, including the ALZ-NET Registry
-
November 14, 2025
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
-
November 7, 2025
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
October 30, 2025
Revenue of LEQEMBI® (Preliminary Basis)
-
October 29, 2025
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
-
October 28, 2025
Merck & Co., Inc., Rahway, NJ, USA and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
First treatment regimen to demonstrate a statistically significant improvement in PFS for patients whose disease progressed following anti-PD-1/L1 therapy, compared with cabozantinib in Phase 3 study
LITESPARK-011 marks the first positive Phase 3 study of a HIF-2 alpha inhibitor in combination with a multi-targeted VEGF tyrosine kinase inhibitor
-
October 27, 2025
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology
-
October 20, 2025
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
At five years, LENVIMA plus KEYTRUDA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the pivotal Phase 3 Study 309/KEYNOTE-775 trial
Five-year OS results in the pMMR subgroup were consistent with the all-comers study population, which demonstrated an OS rate of 19.9% for LENVIMA plus KEYTRUDA versus 7.7% for chemotherapy
-
October 14, 2025
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
-
October 7, 2025
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training,and an injection tracking tool and more
LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months
-
October 2, 2025
Eisai Highlights Breadth of Oncology Research at ESMO 2025
-
September 29, 2025
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
-
September 24, 2025
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
-
September 24, 2025
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
September 17, 2025
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
-
September 12, 2025
“New Answers to Dementia”
Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
-
September 8, 2025
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1
-
September 4, 2025
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
-
September 3, 2025
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease
-
August 30, 2025
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months
LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S.
-
August 29, 2025
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to
Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
-
August 25, 2025
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
-
August 18, 2025
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
-
July 31, 2025
Revenue of LEQEMBI® (Preliminary Basis)
-
July 31, 2025
Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease
56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four Years
-
July 31, 2025
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer’s disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation
-
July 31, 2025
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
-
July 29, 2025
LENVIMA® (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
-
July 25, 2025
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
-
July 23, 2025
Launch of Beova® Tablets in Thailand for Overactive Bladder
-
July 22, 2025
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer’s Association International Conference 2025
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD
AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition
-
July 16, 2025
Eisai Awarded “The 9th Bioindustry Award”
for Drug Discovery Research for Anti- Amyloid β Monoclonal Antibody Lecanemab
-
July 14, 2025
“URECE®” (Dotinurad) Launched in China as a treatment for Gout
-
July 9, 2025
Update on the Cost-Effectiveness Evaluation of LEQEMBI® by the Central Social Insurance Medical Council of Japan’s Ministry of Health, Labour and Welfare
-
July 8, 2025
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
-
June 2, 2025
Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan
- Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product -
-
May 29, 2025
Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
May 27, 2025
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
-
May 21, 2025
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
-
May 16, 2025
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro®
-
May 15, 2025
Notification Regarding Partial Amendment to the Articles of Incorporation
-
May 8, 2025
Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
-
May 1, 2025
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
April 29, 2025
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
-
April 16, 2025
Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology
Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD
-
April 14, 2025
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
-
April 1, 2025
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
-
March 28, 2025
“New Answers to Dementia”
Eisai Launches Corporate Awareness Campaign
-
March 28, 2025
EISAI TO DIVEST RIGHTS FOR PARIET® IN CHINA TO PEAK PHARMA
-
March 27, 2025
Eisai to Divest Rights for Warfarin in Japan to Sawai
-
March 27, 2025
Eisai to Present the Latest Research Results, Including Long-Term and
Real-Word Data on Lecanemab and Biomarkers for Alzheimer’s Disease at the AD/PD™ 2025 Annual Meeting
-
March 25, 2025
World’s First Early Alzheimer’s Disease Treatment Developed in Japan LEQEMBI® Receives Prime Minister’s Award at the 12th Technology Management and Innovation Awards
-
March 24, 2025
EISAI SELECTED AS A NADESHIKO BRAND 2025 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE
-
March 21, 2025
Proton Pump Inhibitor “Pariet® S” Approved in Japan as RX-to-OTC Switch
Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product
-
March 14, 2025
Notice Concerning Commencement of Tender Offer by Eisai Co., Ltd. for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
-
March 10, 2025
EISAI RECOGNIZED AS “2025 KENKO INVESTMENT FOR HEALTH” FOR THE FIRST TIME AND CERTIFIED AS “OUTSTANDING ORGANIZATION OF KENKO INVESTMENT FOR HEALTH PROGRAM (WHITE 500)” FOR THE SIXTH TIME
-
March 7, 2025
Eisai Announces Appointments of Corporate Officers
-
March 7, 2025
Notice of Nominees for Directors
-
March 7, 2025
Notification Regarding Changes in Representative Corporate Officers
-
March 4, 2025
UPDATE ON THE CO-PROMOTION OF THE ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG IN JAPAN
-
March 3, 2025
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
-
March 3, 2025
“Fatigue Recovery While You Sleep!” Eisai to Launch Designated Quasi-Drug Drink “Chocola BB® Nightwell”
Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine
-
February 28, 2025
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
-
February 28, 2025
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
-
February 20, 2025
EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2024” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY” FOR SECOND CONSECUTIVE YEAR,
AS A COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
-
February 14, 2025
DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION FOR EARLY SCREENING OF ALZHEIMER’S DISEASE
MACHINE LEARNING MODEL USING DATA THAT CAN BE COLLECTED IN DAILY MEDICAL EXAMINATIONS BY PRIMARY CARE PHYSICIANS
-
February 6, 2025
Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security
-
February 3, 2025
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
-
January 31, 2025
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
-
January 27, 2025
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of
Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy
-
January 24, 2025
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-015 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
-
January 23, 2025
Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”
-
January 22, 2025
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE NINTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 14, 2025
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience
of a subcutaneous injection with at-home administration option
-
January 7, 2025
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer’s Disease
-
December 23, 2024
Fujirebio and Eisai Enter into Memorandum of Understanding for
Joint Research and Social Implementation of Blood-based Biomarkers
in the Field of Neurodegenerative Diseases
-
December 11, 2024
“URECE®” (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA
-
December 5, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico
-
November 29, 2024
Eisai Announces Completion of Cancellation of Treasury Shares
Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act
-
November 28, 2024
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea
-
November 26, 2024
EISAI SIGNS RESEARCH COLLABORATION AGREEMENT WITH THE NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY TO INITIATE APOLIPOPROTEIN E GENETIC TESTING IN THE “AD-DMT REGISTRY” IN JAPAN
-
November 20, 2024
ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) FOR AMYOTROPHIC LATERAL SCLEROSIS LAUNCHED IN JAPAN
-
November 20, 2024
ANTICANCER AGENT “TASFYGO® TABLETS 35mg” (TASURGRATINIB SUCCINATE) LAUNCHED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION OR REARRANGEMENTS
-
November 15, 2024
NATIONWIDE TV COMMERCIAL LAUNCHED IN JAPAN TO RAISE AWARENESS ABOUT MCI (MILD COGNITIVE IMPAIRMENT)
-
November 15, 2024
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
-
November 5, 2024
Eisai’s Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem’
-
November 1, 2024
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
-
October 31, 2024
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab-
-Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-
-
October 31, 2024
EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease
-
October 30, 2024
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
October 24, 2024
EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER'S
-
October 17, 2024
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Demonstrating the Utility of Blood Biomarkers in Predicting Amyloid Beta Accumulation in the Brain
-
October 17, 2024
UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN AUSTRALIA
-
October 16, 2024
AMYOTROPHIC LATERAL SCLEROSIS TREATMENT “ROZEBALAMIN® FOR INJECTION 25 MG” RECEIVES THE GOOD DESIGN AWARD 2024 FOR LIGHT-PROOF VIAL PACKAGING
-
October 8, 2024
“URECE® TABLETS” (DOTINURAD) APPROVED IN THAILAND FOR GOUT AND HYPERURICEMIA
-
October 4, 2024
Eisai Announces Status and Completion of Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
October 2, 2024
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN SAUDI ARABIA
-
October 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
September 24, 2024
ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS
-
September 24, 2024
ANTICANCER AGENT “TASFYGO® TABLETS 35mg” (TASURGRATINIB SUCCINATE)
APPROVED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSIONS OR REARRANGEMENTS
-
September 17, 2024
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEO FOR WORLD ALZHEIMER’S MONTH
“TODAY FOR TOMORROW”: A DOCUMENTARY OF SIX MONTHS FOLLOWING THE CURRENT STATE OF DEMENTIA
“LEARNING HELPS US TO BE KIND”
-
September 17, 2024
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
In the Phase 3 LEAP-012 trial, LENVIMA plus KEYTRUDA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone
Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024
-
September 12, 2024
Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)
Aiming to establish a drug discovery and development system that accelerates the development of new anticancer drugs
-
September 5, 2024
EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024
-
September 2, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
August 27, 2024
RELEASE OF INSOMNIA AWARENESS VIDEO FOR JAPAN’S AUTUMN SLEEP HEALTH WEEKS
-
August 22, 2024
Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* heterozygotes or non-carriers
Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of AD
-
August 14, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates
-
August 6, 2024
Update Regarding the Regulatory Status of LEQEMBI® Subcutaneous Formulation
-
August 1, 2024
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
August 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
July 31, 2024
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024
- 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
- Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing After Plaque Clearance. Lecanemab’s Dual Action Supports Neuronal Function by Clearing Highly Toxic Protofibrils that Continue to Cause Neuronal Injury and Death After Rapid Plaque Clearance
- Lecanemab Slows Tau Spread Across All Brain Regions
-
July 26, 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
-
July 24, 2024
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
-
July 23, 2024
EISAI TO PRESENT DUAL-ACTING LECANEMAB THREE YEAR EFFICACY AND SAFETY DATA AND DISCUSS LONG-TERM OUTCOMES OF CONTINUED TREATMENT AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2024
Latest findings from Eisai’s robust Alzheimer’s disease (AD) pipeline will be shared, including the importance of continued treatment of AD, which is a progressive neurodegenerative disease that begins before plaque deposition and continues after plaque removal
-
July 16, 2024
EISAI ENTERS INTO LICENSE AGREEMENT FOR FOSRAVUCONAZOLE IN ASIA/OCEANIA WITH SATO PHARMA
-
July 12, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel
-
July 11, 2024
EISAI LISTED FOR 23RD CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES,
AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 11, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
-
July 1, 2024
EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND COMMERCIALIZATION OF FARLETUZUMAB ECTERIBULIN (FZEC) ANTIBODY DRUG CONJUGATE (ADC)
Strategic collaboration with Bristol Myers Squibb ended
-
July 1, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
June 28, 2024
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
China is the Third Country to Launch LEQEMBI Following the United States and Japan
-
June 27, 2024
Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares
-
June 21, 2024
EISAI CONTINUES CONTRACT FOR FY2024 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2023 PAY FOR SUCCESS CONTRACT
-
June 14, 2024
Eisai Announces Appointments of Directors and Corporate Officers
-
June 10, 2024
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
-
June 3, 2024
EISAI NAMED TO LIST OF THE TIME 100 MOST INFLUENTIAL COMPANIES
-
June 3, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
-
June 3, 2024
EISAI STRENGTHENS VENTURE INVESTMENT BUSINESS AIMED AT ACCELERATING DRUG DISCOVERY INNOVATION AND ESTABLISHMENT OF ECOSYSTEM PLATFORM
-
May 27, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea
-
May 23, 2024
EISAI SHOWCASES ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2024
-
May 22, 2024
METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR LAUNCHED IN JAPAN
-
May 15, 2024
Eisai Announces Acquisition of Own Shares and Cancellation of Treasury Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act
-
May 15, 2024
Notice of Nominees for Directors and Corporate Officers
-
May 15, 2024
Notice Concerning Appointment of New Representative Officer
-
May 15, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
-
May 13, 2024
ANTIEPILEPTIC DRUG FYCOMPA® APPROVED IN CHINA FOR ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
-
April 24, 2024
REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
-
April 17, 2024
RESEARCH ON TREATMENTS FOR ALZHEIMER’S DISEASE BASED ON ITS PATHOLOGICAL MECHANISMS RECIEVES AWARD FOR SCIENCE AND TECHNOLOGY (RESEARCH CATEGORY), AS A PART OF FY2024 COMMENDATION FOR SCIENCE AND TECHNOLOGY BY MEXT
-
April 17, 2024
ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION LAUNCHED IN JAPAN
ADDRESSING MEDICAL NEEDS FOR PATIENTS WHO CANNOT TAKE THE MEDICATION ORALLY
-
April 11, 2024
EISAI SUPPORTS RELIEF EFFORTS FOR THE EARTHQUAKE OF THE EAST COAST OF TAIWAN
-
April 2, 2024
FRENCH SALES SUBSIDIARY EISAI S.A.S. TO DIVEST RIGHTS FOR LOXAPAC® AND PARKINANE® LP TO CNX THERAPEUTICS
-
April 1, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA
-
March 29, 2024
EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL
-
March 28, 2024
EISAI’S BRAIN HEALTH SELF-CHECK TOOL “NOUKNOW®” IS CERTIFIED AS “ME-BYO BRAND” BY KANAGAWA PREFECTURE
-
March 28, 2024
DISCOVERY RESEARCH ON DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2024
-
March 25, 2024
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
March 22, 2024
DELIBERATIONS AT THE CHMP REGARDING THE MARKETING AUTHORIZATION APPLICATION IN THE EU FOR LECANEMAB HAVE BEEN RESCHEDULED DUE TO PROCEDURAL REASONS AT THE EUROPEAN MEDICINES AGENCY
-
March 21, 2024
Lifenet and Eisai Co-Develop Dementia Insurance “be”
Supporting early detection and treatment of dementia and mild cognitive impairment (MCI)
-
March 21, 2024
EISAI SELECTED AS A NADESHIKO BRAND 2024 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE
-
March 6, 2024
EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE TO BETTER SERVE PATIENTS
-
February 29, 2024
EISAI TO PRESENT DATA ON LECANEMAB AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING
-
February 21, 2024
EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION,AIMING TO ACHIEVE NET ZERO BY 2050
PARTICIPATION IN JCI RACE TO ZERO CIRCLE AND APPROVAL FOR SBT 1.5°C TARGET
-
February 20, 2024
EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2023” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY”, RECOGNIZED AS COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
-
February 15, 2024
METOJECT® SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR APPROVED IN JAPAN
-
February 1, 2024
EISAI COMMENCES FULLY-FLEDGED BUSINESS ACTIVITIES AT PHARMA SALES SUBSIDIARY IN SOUTH AFRICA
COMMENCEMENT OF DIRECT SALES OPERATIONS IN AFRICA, AND ESTABLISHMENT OF BRANCH OFFICE IN KENYA
-
January 26, 2024
EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS
-
January 18, 2024
ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION APPROVED IN JAPAN
ADDRESSING MEDICAL NEEDS FOR TREATMENT THROUGH A NON-ORAL ADMINISTRATION ROUTE
-
January 17, 2024
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE EIGHTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 16, 2024
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
-
January 11, 2024
THE SCIENTIFIC ADVISORY GROUP (SAG) TO CONVENE TO DISCUSS THE MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB IN THE EU
-
January 9, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China
China is the Third Country to Approve LEQEMBI Following the United States and Japan
-
January 5, 2024
EISAI SUPPORTS RELIEF EFFORTS FOR THE NOTO PENINSULA EARTHQUAKE OF 2024 IN JAPAN
